世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

巣状分節性糸球体硬化症(FSGS)治療の世界市場成長(現状と展望)2024-2030年


Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Growth (Status and Outlook) 2024-2030

巣状分節性糸球体硬化症(FSGS)はまれな腎臓病の一種で、腎臓のろ過器(糸球体)が侵され、蛋白尿と深刻な瘢痕化をもたらす。巣状分節性糸球体硬化症(FSGS)は通常、4~9年以内に腎不全を引き起こし、透析を経... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年5月24日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
109 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

巣状分節性糸球体硬化症(FSGS)はまれな腎臓病の一種で、腎臓のろ過器(糸球体)が侵され、蛋白尿と深刻な瘢痕化をもたらす。巣状分節性糸球体硬化症(FSGS)は通常、4~9年以内に腎不全を引き起こし、透析を経て死に至るため致命的です。FSGSは糖尿病性腎症よりも急速に進行します。大量の蛋白尿、ネフローゼ症候群、浮腫、高脂血症、低アルブミン血症などがこの病気の一般的な症状です。危険因子としては、肥満、感染症、鎌状赤血球症、逆流性腎症などが挙げられる。
世界の巣状分節性糸球体硬化症(FSGS)治療市場規模は、2023年の3億620万米ドルから2030年には4億1560万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は4.5%と予測されています。
LPI(LPインフォメーション)の最新調査レポート「巣状分節性糸球体硬化症(FSGS)治療薬産業の予測」は、過去の売上高を調査し、2023年の世界の巣状分節性糸球体硬化症(FSGS)治療薬の総売上高をレビューし、2024年から2030年までの巣状分節性糸球体硬化症(FSGS)治療薬の予測売上高を地域別・市場分野別に包括的に分析しています。巣状分節性糸球体硬化症(FSGS)治療薬の売上高を地域別、市場分野別、サブセクター別に分類し、世界の巣状分節性糸球体硬化症(FSGS)治療薬産業の詳細な分析を百万米ドル単位で提供しています。
このインサイトレポートでは、世界の巣状分節性糸球体硬化症(FSGS)治療産業の状況を包括的に分析し、製品セグメンテーション、企業形成、収益、市場シェア、最新動向、M&A活動などに関する主要動向を明らかにします。また本レポートでは、焦点性分節性糸球体硬化症(FSGS)治療薬のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当てて、世界の主要企業の戦略を分析し、加速する世界の焦点性分節性糸球体硬化症(FSGS)治療薬市場におけるこれらの企業の独自の地位をより深く理解しています。
本インサイトレポートでは、巣状分節性糸球体硬化症(FSGS)治療薬の世界的な見通しを形成する主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を細分化して、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの質的・量的市場インプットに基づいた透明性の高い手法により、この調査予測は世界の巣状分節性糸球体硬化症(FSGS)治療の現状と将来の軌道について非常にニュアンスのある見解を提供します。
世界の医薬品市場は2022年に1,475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤が含まれる。生物学的製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調しています。
本レポートでは、巣状分節性糸球体硬化症(FSGS)治療市場の包括的な概要、市場シェア、成長機会を、製品タイプ別、用途別、主要企業別、主要地域・国別に紹介します。
タイプ別セグメンテーション
薬物療法
透析療法
腎移植
用途別セグメント
原発性FSGS
二次性FSGS
本レポートではまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
メドトロニック
メドトロニック
ファイザー
コンプレクサ
ダイメリックス
レトロフィン
ベックマン・コールター(ダナハー)
ボストン・サイエンティフィック社
ケモセントリックス
バリアント・ファーマシューティカルズ


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2019-2030
2.1.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Segment by Type
2.2.1 Drug Therapy
2.2.2 Dialysis
2.2.3 Kidney Transplant
2.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
2.3.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)
2.4 Focal Segmental Glomerulosclerosis (FSGS) Treatment Segment by Application
2.4.1 Primary FSGS
2.4.2 Secondary FSGS
2.5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
2.5.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)
3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Player
3.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Players
3.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Players (2019-2024)
3.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Focal Segmental Glomerulosclerosis (FSGS) Treatment by Regions
4.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions (2019-2024)
4.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)
4.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)
4.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2019-2024)
5.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)
5.3 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2019-2024)
6.2 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)
6.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment by Country (2019-2024)
7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)
7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment by Region (2019-2024)
8.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Regions (2025-2030)
10.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast
10.1.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast
10.1.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast
10.1.5 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast
10.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Country (2025-2030)
10.2.1 United States Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.2.2 Canada Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.2.3 Mexico Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.2.4 Brazil Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Region (2025-2030)
10.3.1 China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.2 Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.3 Korea Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.4 Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.5 India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.6 Australia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Country (2025-2030)
10.4.1 Germany Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4.2 France Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4.3 UK Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4.4 Italy Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4.5 Russia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5.2 South Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5.3 Israel Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5.4 Turkey Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5.5 GCC Countries Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.6 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Type (2025-2030)
10.7 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 B. Braun Melsungen
11.1.1 B. Braun Melsungen Company Information
11.1.2 B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.1.3 B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 B. Braun Melsungen Main Business Overview
11.1.5 B. Braun Melsungen Latest Developments
11.2 Medtronic
11.2.1 Medtronic Company Information
11.2.2 Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.2.3 Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Medtronic Main Business Overview
11.2.5 Medtronic Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.3.3 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Complexa
11.4.1 Complexa Company Information
11.4.2 Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.4.3 Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Complexa Main Business Overview
11.4.5 Complexa Latest Developments
11.5 Dimerix
11.5.1 Dimerix Company Information
11.5.2 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.5.3 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Dimerix Main Business Overview
11.5.5 Dimerix Latest Developments
11.6 Retrophin
11.6.1 Retrophin Company Information
11.6.2 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.6.3 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Retrophin Main Business Overview
11.6.5 Retrophin Latest Developments
11.7 Beckman Coulter Inc. (Danaher)
11.7.1 Beckman Coulter Inc. (Danaher) Company Information
11.7.2 Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.7.3 Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Beckman Coulter Inc. (Danaher) Main Business Overview
11.7.5 Beckman Coulter Inc. (Danaher) Latest Developments
11.8 Boston Scientific Corporation
11.8.1 Boston Scientific Corporation Company Information
11.8.2 Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.8.3 Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Boston Scientific Corporation Main Business Overview
11.8.5 Boston Scientific Corporation Latest Developments
11.9 ChemoCentryx
11.9.1 ChemoCentryx Company Information
11.9.2 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.9.3 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 ChemoCentryx Main Business Overview
11.9.5 ChemoCentryx Latest Developments
11.10 Variant Pharmaceuticals
11.10.1 Variant Pharmaceuticals Company Information
11.10.2 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.10.3 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Variant Pharmaceuticals Main Business Overview
11.10.5 Variant Pharmaceuticals Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

Focal segmental glomerulosclerosis (FSGS) is a type of rare kidney disease that affects the kidney’s filtering system (glomeruli) resulting in proteinuria and serious scarring. Focal segmental glomerulosclerosis (FSGS) is usually fatal since it causes kidney failure within four to nine years followed by dialysis and then death. FSGS advances much more swiftly than diabetic nephropathy. Massive proteinuria, nephrotic syndrome, edema, hyperlipidemia, and hypoalbuminemia are some of the common symptoms of the disease. Risk factors include obesity, infection, sickle cell disease and reflux nephropathy.
The global Focal Segmental Glomerulosclerosis (FSGS) Treatment market size is projected to grow from US$ 306.2 million in 2023 to US$ 415.6 million in 2030; it is expected to grow at a CAGR of 4.5% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Focal Segmental Glomerulosclerosis (FSGS) Treatment Industry Forecast” looks at past sales and reviews total world Focal Segmental Glomerulosclerosis (FSGS) Treatment sales in 2023, providing a comprehensive analysis by region and market sector of projected Focal Segmental Glomerulosclerosis (FSGS) Treatment sales for 2024 through 2030. With Focal Segmental Glomerulosclerosis (FSGS) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Focal Segmental Glomerulosclerosis (FSGS) Treatment industry.
This Insight Report provides a comprehensive analysis of the global Focal Segmental Glomerulosclerosis (FSGS) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Focal Segmental Glomerulosclerosis (FSGS) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Focal Segmental Glomerulosclerosis (FSGS) Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Focal Segmental Glomerulosclerosis (FSGS) Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Focal Segmental Glomerulosclerosis (FSGS) Treatment.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Focal Segmental Glomerulosclerosis (FSGS) Treatment market by product type, application, key players and key regions and countries.
Segmentation by type
Drug Therapy
Dialysis
Kidney Transplant
Segmentation by application
Primary FSGS
Secondary FSGS
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
B. Braun Melsungen
Medtronic
Pfizer
Complexa
Dimerix
Retrophin
Beckman Coulter Inc. (Danaher)
Boston Scientific Corporation
ChemoCentryx
Variant Pharmaceuticals



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size 2019-2030
2.1.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Segment by Type
2.2.1 Drug Therapy
2.2.2 Dialysis
2.2.3 Kidney Transplant
2.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
2.3.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Type (2019-2024)
2.4 Focal Segmental Glomerulosclerosis (FSGS) Treatment Segment by Application
2.4.1 Primary FSGS
2.4.2 Secondary FSGS
2.5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
2.5.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Application (2019-2024)
3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Player
3.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Market Share by Players
3.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Players (2019-2024)
3.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Focal Segmental Glomerulosclerosis (FSGS) Treatment by Regions
4.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions (2019-2024)
4.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)
4.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)
4.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2019-2024)
5.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)
5.3 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2019-2024)
6.2 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)
6.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment by Country (2019-2024)
7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)
7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment by Region (2019-2024)
8.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Regions (2025-2030)
10.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast
10.1.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast
10.1.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast
10.1.5 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast
10.2 Americas Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Country (2025-2030)
10.2.1 United States Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.2.2 Canada Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.2.3 Mexico Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.2.4 Brazil Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3 APAC Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Region (2025-2030)
10.3.1 China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.2 Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.3 Korea Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.4 Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.5 India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.3.6 Australia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Country (2025-2030)
10.4.1 Germany Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4.2 France Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4.3 UK Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4.4 Italy Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.4.5 Russia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5.2 South Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5.3 Israel Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5.4 Turkey Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.5.5 GCC Countries Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast
10.6 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Type (2025-2030)
10.7 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 B. Braun Melsungen
11.1.1 B. Braun Melsungen Company Information
11.1.2 B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.1.3 B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 B. Braun Melsungen Main Business Overview
11.1.5 B. Braun Melsungen Latest Developments
11.2 Medtronic
11.2.1 Medtronic Company Information
11.2.2 Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.2.3 Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Medtronic Main Business Overview
11.2.5 Medtronic Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.3.3 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Complexa
11.4.1 Complexa Company Information
11.4.2 Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.4.3 Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Complexa Main Business Overview
11.4.5 Complexa Latest Developments
11.5 Dimerix
11.5.1 Dimerix Company Information
11.5.2 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.5.3 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Dimerix Main Business Overview
11.5.5 Dimerix Latest Developments
11.6 Retrophin
11.6.1 Retrophin Company Information
11.6.2 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.6.3 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Retrophin Main Business Overview
11.6.5 Retrophin Latest Developments
11.7 Beckman Coulter Inc. (Danaher)
11.7.1 Beckman Coulter Inc. (Danaher) Company Information
11.7.2 Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.7.3 Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Beckman Coulter Inc. (Danaher) Main Business Overview
11.7.5 Beckman Coulter Inc. (Danaher) Latest Developments
11.8 Boston Scientific Corporation
11.8.1 Boston Scientific Corporation Company Information
11.8.2 Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.8.3 Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Boston Scientific Corporation Main Business Overview
11.8.5 Boston Scientific Corporation Latest Developments
11.9 ChemoCentryx
11.9.1 ChemoCentryx Company Information
11.9.2 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.9.3 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 ChemoCentryx Main Business Overview
11.9.5 ChemoCentryx Latest Developments
11.10 Variant Pharmaceuticals
11.10.1 Variant Pharmaceuticals Company Information
11.10.2 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Offered
11.10.3 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Variant Pharmaceuticals Main Business Overview
11.10.5 Variant Pharmaceuticals Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/24 10:26

158.45 円

165.22 円

201.28 円

ページTOPに戻る